Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5686746 | The Journal of Urology | 2017 | 28 Pages |
Abstract
For nonmuscle invasive bladder cancer several intravesical therapies are associated with a decreased risk of recurrence vs transurethral bladder tumor resection alone. Bacillus Calmette-Guérin is the only agent associated with a decreased progression risk vs transurethral bladder tumor resection alone, but may be associated with a higher risk of adverse events than other intravesical therapies, indicating trade-offs between potential benefits and harms.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Roger Chou, Shelley Selph, David I. Buckley, Rongwei Fu, Jessica C. Griffin, Sara Grusing, John L. Gore,